Destiny Pharma plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Destiny Pharma plc
Companies in talks with EU authorities for the supply of at least 200 million initial doses of their mRNA vaccine. Plus, other new partnerships around the world and an India pause for AstraZeneca's contender in line with global decision.
The SPOR-COV prophylactic approach targets the innate immune system and has the potential to develop COVID-19 protection within a few days of treatment, the partners tell Scrip.
Destiny’s Phase IIb clinical study of lead asset XF-73 in the prevention of post-surgical bacterial infections got a boost from trial protocol amendments agreed with the FDA.
Antimicrobial specialist Destiny Pharma aims to enlist a pharma partner later this year to help advance and launch its lead asset for preventing post-surgical infections.